Menlo Therapeutics Inc is a biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, associated with dermatologic conditions such as ...

Today we look at one noteworthy recent insider buy. On Wednesday, VYNE Therapeutics', Patrick G. Lepore, made a $43,800 buy of VYNE, purchasing 15,000 shares at a cost of $2.92 each. Bargain ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

VYNE Therapeutics (VYNE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The VYN201 gel is intended to treat non-segmental vitiligo. Credit: Prostock-studio / Shutterstock. US-based pharmaceutical company VYNE Therapeutics has completed enrolment in the randomised Phase ...

06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to ...

VYN-201 is under clinical development by VYNE Therapeutics and currently in Phase II for Vitiligo. According to GlobalData, Phase II drugs for Vitiligo have a 42% phase transition success rate (PTSR) ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...